JUNIPER PHARMACEUTICALS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-11-21: Form 8-K/A; Period of report 2013-09-12; Description 9.01 Financial Statements and Exhibits; Details 9.01.
- 2013-11-18: Form 8-K; Period of report 2013-11-11; Description 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 7.01 Regulation FD Disclosure; Details 1.01.
- 2013-11-07: Form 8-K; Period of report 2013-11-07; Description 2.02 Results of Operations and Financial Condition.
- 2013-09-18: Form 8-K; Period of report 2013-09-12; Description 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-11-21 | 8-K/A | 2013-09-12 | 9.01 Financial Statements and Exhibits | 9.01 Audited financial statements of Molecular Profiles Limited (in British pounds sterling) as of July 31, 2013 and 2012, including an audited note reconciling UK GAAP to US GAAP for 2013 and 2012 are attached hereto as Exhibit 99.1. | d631542d8ka.htm |
| 2013-11-18 | 8-K | 2013-11-11 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 1.02 Pursuant to the Termination Agreement, the Company and Coventry agreed to terminate that certain Supply Agreement, dated July 2, 2010 (the “Supply Agreement”), between the Company and Coventry. 7.01 On November 14, 2013, the Company issued a press release entitled “Columbia Laboratories to receive One-time Payment from Actavis for CRINONE U.S. Manufacturing Rights” in connection with the termination of the Supply Agreement. | d630377d8k.htm |
| 2013-11-07 | 8-K | 2013-11-07 | 2.02 Results of Operations and Financial Condition | d626562d8k.htm | |
| 2013-09-18 | 8-K | 2013-09-12 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 2.01 The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. 2.03 On September 5, 2013, Molecular Profiles entered into a grant letter (the “Grant Letter”) with the Secretary of State for Business, Innovation and Skills. 5.02 On September 10, 2013, the board of directors (the “Board”) of the Company voted to increase the size of the Board from six to eight members and to appoint Dr. Nikin Patel and Dr. Frank Armstrong as new directors to fill the vacancies created by such increase, contingent upon the closing of the acquisition. 7.01 On September 12, 2013, the Company issued a press release announcing the closing of the Company’s acquisition of Molecular Profiles. | d598523d8k.htm |
| 2013-09-12 | 8-K | 2013-09-12 | 7.01 Regulation FD Disclosure | 7.01 On September 12, 2013, Columbia Laboratories, Inc. (the “Company”) issued a press release entitled “Columbia Laboratories Acquires Molecular Profiles Ltd., a U.K.-Based Provider of Pharmaceutical Formulation Development and Manufacturing Services”, announcing the closing of the Company’s acquisition of Molecular Profiles Limited. | d597231d8k.htm |
| 2013-08-08 | 8-K | 2013-08-08 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure | 5.03 On August 8, 2013, Columbia Laboratories, Inc. (the “Company”) announced that it had filed a Certificate of Amendment to its Restated Certificate of Incorporation (the “Amendment”) with the Secretary of the State of Delaware to effect a 1-for-8 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding common stock, par value $0.01 per share (the “Common Stock”). 7.01 The Company announced the matters described in Item 5.03 above in a press release entitled “Columbia Laboratories Announces One-For-Eight Reverse Stock Split” on August 8, 2013. | d581022d8k.htm |
| 2013-08-07 | 8-K | 2013-08-07 | 2.02 Results of Operations and Financial Condition | d575576d8k.htm | |
| 2013-07-26 | 8-K | 2013-07-26 | 8.01 Other Events | 8.01 On July 26, 2013, Columbia Laboratories, Inc. (the “Company”) issued a press release entitled “Columbia Laboratories’ Board Approves 1-for-8 Reverse Stock Split” (the “Press Release”), announcing that the Board of Directors of the Company (the “Board”) set a ratio of 1-for-8 for a reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”) and an anticipated effective date for the Reverse Stock Split of the later of (i) the filing of a certificate of amendment with respect to the Reverse Stock Split or (ii) August 9, 2013 (the “Effective Date”). | d572113d8k.htm |
| 2013-06-12 | 8-K | 2013-06-11 | 7.01 Regulation FD Disclosure | 7.01 Regulation FD Disclosure; 8.01. | d555351d8k.htm |
| 2013-05-09 | 8-K | 2013-05-09 | 2.02 Results of Operations and Financial Condition | d535778d8k.htm | |
| 2013-05-03 | 8-K | 2013-05-01 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 At the Company’s Annual Meeting, six proposals were submitted to and approved by the stockholders. | d530680d8k.htm |
| 2013-05-02 | 8-K | 2013-05-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.07 At the Company’s Annual Meeting, six proposals were submitted to and approved by the stockholders. | d530680d8k.htm |
| 2013-04-24 | 8-K | 2013-04-23 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On April 23, 2013, Columbia Laboratories, Inc. (the “Company”) received notification (the “Nasdaq Letter”) from Nasdaq Stock Market (“Nasdaq”) indicating that the Company’s application to list its common stock on the Nasdaq Capital Market has been approved. | d526941d8k.htm |
| 2013-04-09 | 8-K | 2013-04-04 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 7.01 On April 4, 2013, the Company issued a press release entitled, “Columbia Laboratories Extends Agreement with Merck Serono for CRINONE Ex-U.S. into 2020” (the “Press Release”). | a8-kseronorenewalagreement.htm |
| 2013-03-14 | 8-K | 2013-03-14 | 7.01 Regulation FD Disclosure | 7.01 On March 14, 2013, Columbia Laboratories, Inc. (the “Company”) held a conference call (the “Conference Call”) to discuss fourth quarter and year-end 2012 financial results. | a2012yecalltranscript8kform.htm |
| 2013-03-14 | 8-K | 2013-03-14 | 2.02 Results of Operations and Financial Condition | 2.02 On March 14, 2013, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, "Columbia Laboratories Reports Fourth Quarter and Year-End 2012 Financial Results" (the “Press Release”). | a8-k2012q4pressrelease.htm |
| 2013-03-06 | 8-K | 2013-03-01 | 1.01 Entry into a Material Definitive Agreement; 3.03 Material Modification to Rights of Security Holders; 7.01 Regulation FD Disclosure | 1.01 On March 1, 2013, the board of directors of Columbia Laboratories, Inc. (the “Company”) approved a second amendment (“Amendment No. 2”) to the Company's Amended and Restated Rights Agreement, dated as of November 29, 2010, as amended as of September 20, 2011 (the “Rights Agreement”), to extend the expiration date of the rights contained therein from July 3, 2013 to July 3, 2016. 3.03 The disclosures set forth under Item 1.01 are incorporated by reference into this Item 3.03. 7.01 A copy of the press release announcing the Amendment is furnished herewith as Exhibit 99.1. | a8-kamendmentandrestatedri.htm |
| 2013-03-05 | 8-K | 2013-03-05 | 7.01 Regulation FD Disclosure | 7.01 Frank C. Condella, Jr., president and chief executive officer of Columbia Laboratories, Inc. (the “Company”), and Jonathan Lloyd Jones, the Company's vice president and chief financial officer, will present to various investors beginning March 5, 2013. | march52013.htm |
| 2013-01-16 | 8-K | 2013-01-15 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 1.02 On January 15, 2013, the Company terminated without Cause the Employment Agreement dated July 15, 2009, with Lawrence A. Gyenes, as Senior Vice President, Chief Financial Officer, and Treasurer of the Company (the “Gyenes Agreement”). 5.02 On January 15, 2013, Jonathan B. Lloyd Jones was appointed Vice President Finance, Chief Financial Officer, Treasurer, and Secretary of the Company effective January 21, 2013. 8.01 On January 16, 2013, Columbia Laboratories, Inc. issued a press release entitled, “Jonathan B. Lloyd Jones Appointed CFO of Columbia Laboratories” (the “Press Release”). | form8klloydjones.htm |